Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III drugs for Oropharyngeal Cancer have a 17% phase ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $42 from $33 and keeps a Buy rating on the shares.

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

In addition to Cabozantinib, Exelixis is developing zanzalintinib, a next-generation tyrosine kinase inhibitor. Analysts project that zanzalintinib could generate $5 billion in revenue by 2033, ...

Zanzalintinib stands out as Exelixis’ most clinically advanced asset with potential to become a primary contributor in the medium to long term, says the analyst, who is incorporating zanza into ...

The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...

The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due ...

The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due to ...